Litigation

Celgene Corp. v. Dr. Reddy's Laboratories, Inc.

settled
Filed
2016-10-20
Terminated
2020-09-17

Patents at issue (1)

Plaintiffs (1)

Summary

Celgene sued Dr. Reddy's Laboratories in D.N.J. over generic lenalidomide, with U.S. 7,855,217 among the asserted patents. The case settled, and a consent judgment was entered on September 17, 2020, with Dr. Reddy's agreeing not to market generic Revlimid until expiration of the asserted patents. The docket number was not directly confirmed in the narrative.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 7855217-celgene-corp-v-dr-reddy-s-laboratories-inc · edit in Admin